The role of radiotherapy in the treatment of liver metastases

Cancer Journal

Volumn 10, Issue 2, 2004, Pages 139-144

  Dawson, Laura A ^a,b   Lawrence, Theodore S ^a,c  

^a University of Toronto ^*

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Conformal radiotherapy; Liver metastases

Indexed keywords

ANTINEOPLASTIC AGENT; FLOXURIDINE;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; DOSE RESPONSE; HUMAN; LIVER CIRCULATION; LIVER METASTASIS; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; TREATMENT OUTCOME; COLORECTAL TUMOR; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; RADIOTHERAPY DOSAGE;

EID: 4544350893     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200403000-00009     Document Type: Review

References (45)

1. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318; discussion 18-21.
2. Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 1996;77:1254-1262.
3. Ravikumar TS, Gallos G. Resection of liver metastases: state of the art. Oncology (Huntingt) 2002;16:1240-1256; discussion 58-60, 63.
4. Scheele J, Stang R, Altendorf-Hofmann A et al. Resection of colorectal liver metastases. World J Surg 1995;19:59-71.
5. O'Connell MJ, Nagorney DM, Bernath AM et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528-2533.
6. Allgaier HP, Deibert P, Olschewski M et al. Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients. Int J Cancer 1998;79:601-605.
7. Giorgio A, Tarantino L, Mariniello N et al. Percutaneous ethanol injection under general anesthesia for hepatocellular carcinoma: 3 year survival in 112 patients. Eur J Ultrasound 1998;8:201-206.
8. Pergolizzi JV Jr, Auster M, Conaway GL et al. Cryosurgery for unresectable primary hepatocellular carcinoma: a case report and review of literature. Am Surg 1999;65:402-405.
9. Sarantou T, Bilchik A, Ramming K. Cryoablation of primary and metastatic liver cancer unresponsive to conventional therapy [abstract 1082]. Proc ASCO 1997;16:p. 304A.
10. Rhim H, Dodd GD 3rd. Radiofrequency thermal ablation of liver tumors. J Clin Ultrasound 1999;27:221-229.
11. Murakami T, Shibata T, Ishida T et al. Percutaneous microwave hepatic tumor coagulation with segmental hepatic blood flow occlusion in seven patients. AJR Am J Roentgenol 1999;172:637-640.
12. Ingold J, Reed G, Kaplan H. Radiation hepatitis. Am J Roentgenol 1965;93:200-208.
13. Wharton JT, Delclos L, Gallager S et al. Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 1973;117:73-80.
14. Ohara K, Okumura T, Tsuji H et al. Radiation tolerance of cirrhotic livers in relation to the preserved functional capacity: analysis of patients with hepatocellular carcinoma treated by focused proton beam radiotherapy. Int J Radiat Oncol Biol Phys 1997;38:367-372.
15. Matsuzaki Y, Osuga T, Chiba T et al. New, effective treatment using proton irradiation for unresectable hepatocellular carcinoma. Intern Med 1995;34:302-304.
16. Lawrence TS, Robertson JM, Anscher MS et al. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-1248.
17. Gray B, Hazel GV, Hope M et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 2001;12:1711-1720.
18. Ten Haken RK, Lawrence TS, McShan DL et al. Technical considerations in the use of 3-D beam arrangements in the abdomen. Radiother Oncol 1991;22:19-28.
19. Matsuura M, Nakajima N, Arai K et al. The usefulness of radiation therapy for hepatocellular carcinoma. Hepatogastroenterology 1998;45:791-796.
20. Dawson LA, McGinn CJ, Normolle D et al. Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18:2210-2218.
21. Lawrence TS, Ten Haken RK, Kessler ML et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992;23:781-788.
22. Ohara K, Okumura T, Tsuji H et al. Clearance of parenchymal tumors following radiotherapy: analysis of hepatocellular carcinomas treated by proton beams. Radiother Oncol 1996;41:233-236.
23. Breedis C, Young C. The blood supply of neoplasm in the liver. Am J Pathol 1954;30:969-974.
24. Sigurdson ER, Ridge JA, Kemeny N et al. Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 1987;5:1836-1840.
25. Ensminger WD. Regional chemotherapy. Semin Oncol 1993;20:3-11.
26. Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer: Meta-Analysis Group in Cancer. J Natl Cancer Inst 1996;88:252-258.
27. Harmantas A, Rotstein LE, Langer B. Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Is there a survival difference? Meta-analysis of the published literature. Cancer 1996;78:1639-1645.
28. Russell AH, Clyde C, Wasserman TH et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993;27:117-123.
29. Borgelt BB, Gelber R, Brady LW et al. The palliation of hepatic metastases: results of the Radiation Therapy Oncology Group pilot study. Int J Radiat Oncol Biol Phys 1981;7:587-591.
30. Schacter L, Crum E, Spitzer T et al. Fatal radiation hepatitis: a case report and review of the literature. Gynecol Oncol 1986;24:373-380.
31. McCracken JD, Weatherall TJ, Oishi N et al. Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study. Cancer Treat Rep 1985;69:129-131.
32. Lawrence TS, Dworzanin LM, Walker-Andrews SC et al. Treatment of cancers involving the liver and porta hepatis with external beam irradiation and intraarterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys 1991;20:555-561.
33. Dawson LA, Normolle D, Balter JM et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810-821.
34. McGinn CJ, Ten Haken RK, Ensminger WD et al. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol 1998;16:2246-2252.
35. Ten Haken RK, Martel MK, Kessler ML et al. Use of Veff and iso-NTCP in the implementation of dose escalation protocols. Int J Radiat Oncol Biol Phys 1993;27:689-695.
36. Robertson JM, Lawrence TS, Andrews JC et al. Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 1997;37:325-330.
37. Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 1996;14:722-728.
38. Blomgren H, Lax I, Naslund I et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator: clinical experience of the first thirty-one patients. Acta Oncol 1995;34:861-870.
39. Herfarth KK, Debus J, Lohr F et al. Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 2001;19:164-170.
40. Wulf J, Hadinger U, Oppitz U et al. Stereotactic radiotherapy of targets in the lung and liver. Strahlenther Onkol 2001;177:645-655.
41. Sumi H, Ohtsu A, Boku N et al. A case of inoperable esophageal carcinoma with hepatic and nodal metastases which showed a long-term survival after chemoradiotherapy including nedaplatin. Japan J Clin Oncol 2000;30:406-409.
42. Stansby G, Bhattacharya S, Hilson AJ et al. Case report: localization of lipiodol-radioiodine in hepatic metastases from renal cell carcinoma. Br J Radiol 1994;67:822-824.
43. Yu L, Fleckman AM, Chadha M et al. Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Am J Clin Oncol 1996;19:389-393.
44. Dawson LA, Brock KK, Kazanjian S et al. The reproducibility of organ position using active breathing control (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1410-1421.
45. Symon Z, Levi M, Ensminger WD et al. Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model. Int J Radiat Oncol Biol Phys 2001;50:473-478.